Silva Paul M Form 4 January 24, 2018

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to

Section 16.

Form 4 or Form 5 obligations may continue. See Instruction

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

(Last)

**AVENUE** 

1. Name and Address of Reporting Person \*

Silva Paul M

(First) (Middle)

C/O VERTEX **PHARMACEUTICALS** INCORPORATED, 50 NORTHERN

(Street)

Filed(Month/Day/Year)

BOSTON, MA 02210

2. Issuer Name and Ticker or Trading

Symbol

VERTEX PHARMACEUTICALS INC / MA [VRTX]

3. Date of Earliest Transaction (Month/Day/Year)

4. If Amendment, Date Original

01/22/2018

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

**OMB APPROVAL** 

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

**OMB** 

Number:

Expires:

response...

10% Owner Director X\_ Officer (give title Other (specify

below) SVP & Corp Controller

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 6. 7. Nature of Transaction(A) or Disposed of (D) Ownership Indirect Security (Month/Day/Year) Execution Date, if Securities (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Direct Beneficial (Month/Day/Year) (Instr. 8) Owned (D) or Ownership Following Indirect (I) (Instr. 4) Reported (Instr. 4) (A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price Common 01/22/2018 M 2,427 \$ 86.52 19,061 D Α Stock Common 01/22/2018  $S^{(1)}$ 2,427 D 16,634 D Stock 161.52 Common 01/23/2018 M 1,289 Α \$ 91.05 17,923 D Stock Common 01/23/2018 1,719 \$ 90.29 19,642 D M Α Stock

### Edgar Filing: Silva Paul M - Form 4

|   | Persons who respond to the collection of |      |       |   |              |        |   |        |  |
|---|--|------|-------|---|--------------|--------|---|--------|--|
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |  |      |       |   |              |        |   |        |  |
| Common<br>Stock   |  |      |       |   |              | 169    | I | 401(k) |  |
| Common<br>Stock   | 01/23/2018                               | S(1) | 3,008 | D | \$<br>166.05 | 16,634 | D |        |  |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

8. I De Sec (In

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) |     |      | 6. Date Exerc<br>Expiration D<br>(Month/Day/ | ate                | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |  |
|---|---|--------------------------------------|---|--|-----|------|--|--------------------|---|--|
|   |   |                                      |   | Code V                                 | (A) | (D)  | Date<br>Exercisable                          | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |
| Stock<br>Option<br>(Right to<br>Buy)                | \$ 86.52  | 01/22/2018                           |   | M                                      | 2,  | ,427 | <u>(2)</u>                                   | 02/02/2027         | Common<br>Stock   | 2,427                                  |
| Stock<br>Option<br>(Right to<br>Buy)                | \$ 91.05  | 01/23/2018                           |   | M                                      | 1,  | ,289 | <u>(3)</u>                                   | 02/01/2026         | Common<br>Stock   | 1,289                                  |
| Stock<br>Option<br>(Right to<br>Buy)                | \$ 90.29  | 01/23/2018                           |   | M                                      | 1,  | ,719 | <u>(4)</u>                                   | 07/11/2026         | Common<br>Stock   | 1,719                                  |

## **Reporting Owners**

| Reporting Owner Name / Address          | Relationships |           |                       |       |  |  |  |
|---|---------------|-----------|-----------------------|-------|--|--|--|
| ·                                       | Director      | 10% Owner | Officer               | Other |  |  |  |
| Silva Paul M                            |               |           | SVP & Corp Controller |       |  |  |  |
| C/O VERTEX PHARMACEUTICALS INCORPORATED |               |           |                       |       |  |  |  |
| 50 NORTHERN AVENUE                      |               |           |                       |       |  |  |  |

Reporting Owners 2

BOSTON, MA 02210

## **Signatures**

/s/ Omar White, Attorney-in-Fact 01/24/2018

\*\*Signature of Reporting Person

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1.

Date

- (2) The option vests in 16 quarterly installments from 2/3/2017.
- (3) The option vests in 16 quarterly installments from 2/2/2016.
- (4) The option vests in 16 quarterly installments from 7/12/2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3